JCR Pharmaceuticals Co.,Ltd
4552・Prime Market・Pharmaceuticals
Business
JCR Pharmaceuticals, founded in 1975, is a specialty manufacturer focused on rare diseases and biopharmaceuticals. Centered on its proprietary blood-brain barrier crossing technology "J-Brain Cargo®," the company conducts research and development, manufacturing, and sales of therapeutics for intractable diseases such as lysosomal storage disorders, growth hormone deficiency, and Duchenne muscular dystrophy. Domestically, it sells its own products including "GROWJECT®" and "IZCARGO®," while also generating revenue from out-licensing of its development pipeline and technology licensing income. The group consists of 8 consolidated subsidiaries and 1 equity-method affiliate, and has established a global structure with clinical development sites in the United States, Europe, and Brazil. Listed on the Tokyo Stock Exchange Prime Market.
Business Model
Domestic product sales (¥32,446 million in FY2026 (ending March 2026)) serve as a stable revenue base, combined with growth revenue from contract fees, milestone payments, and royalty income (¥5,549 million in the same period) generated through the external licensing of proprietary technologies "J-Brain Cargo®" and "JUST-AAV". While approximately 63.7% of product sales depend on distribution through Medipal Holdings, the company seeks to diversify revenue through technology licensing agreements with global pharmaceutical companies such as Alexion AstraZeneca Rare Disease and Acumen Pharmaceuticals.
Company Strengths
The company possesses J-Brain Cargo®, a proprietary technology applicable to more than 17 types of lysosomal storage disease treatments. Achievement of the target enrollment for the JR-141 global Phase 3 trial and the track record of concluding out-licensing agreements with multiple global pharmaceutical companies including Alexion, AstraZeneca, RA (Rare Disease Company), Acumen Pharmaceuticals, and Angelini Pharma underpin the technology's competitive advantage.
Multiple products are at clinical stages, including JR-141 (Phase 3), JR-171 (Phase 1/2 completed), JR-441 (Phase 1/2 ongoing), and JR-446 (Phase 1/2 initiated). JR-441 has obtained orphan drug designation from the EC, FDA, and MHLW, while JR-446 has obtained orphan drug designation from the FDA, EC, and MHLW, securing preferential regulatory treatment.
GROWJECT® maintained its top market share through increased sales volume even amid the impact of drug price revisions (net sales of ¥17,933 million). IZCARGO® continued to grow, increasing 18.3% year on year to ¥6,766 million. Total product sales trended stably at ¥32,446 million (up 2.5% year on year).
ENVALITH's Perspective
Performance Trend
Revenue increased +21.9% from ¥33,072 million in FY2025 to ¥40,319 million in FY2026. Product sales remained solid at ¥32,446 million (+2.5%), while the main driver was a sharp increase in contract revenue from ¥517 million to ¥5,549 million. Operating profit turned positive, swinging from ¥-6,219 million to ¥555 million, and profit attributable to owners of parent also recovered from ¥-4,460 million to ¥2,178 million. Subsidy income of ¥1,882 million (finalization of the Kobe Science Park Center subsidy), recorded as extraordinary income, also contributed. On the other hand, the forecast for FY2027 (ending March 2027) calls for revenue of ¥45,700 million (+13.3%), but due to increased R&D expenses, ordinary profit is expected to decline sharply to ¥500 million (-57.1%) and net profit to ¥200 million (-90.8%), indicating that the quality of earnings remains fragile.
Growth Strategy
Strengthening the revenue base through advancement of the J-Brain Cargo® pipeline approval application and diversification of technology licensing
JR-141, a treatment for Hunter syndrome, achieved the target enrollment of subjects in its global Phase 3 clinical trial. A regulatory strategy meeting with the FDA regarding the approval application was held in June 2025, and if the application and approval are realized, it is expected to become a medium- to long-term revenue pillar.
The company entered into a licensing option agreement with Acumen Pharmaceuticals (for Alzheimer's disease) in July 2025, and a JUST-AAV license agreement with Alexion, AstraZeneca Rare Disease in July 2025. The company is promoting diversification of upfront payment and milestone revenue through technology out-licensing.
In December 2025, the company acquired exclusive licensing rights in Japan from Italfarmaco. The drug is already marketed in Europe and the United States as Duvyzat®, and the company is considering a clinical development plan in Japan with the aim of obtaining early approval. The upfront payment has already contributed to the increase in contract revenue for FY2026 (ending March 2026).
The company is proceeding with construction of a new formulation plant selected under the Ministry of Economy, Trade and Industry's project for developing biopharmaceutical manufacturing bases to strengthen vaccine production capacity. Construction in progress has expanded to ¥19,411 million. The construction utilizes government subsidies, and a significant expansion of manufacturing capacity is expected upon completion.
The company established a new research base, the "Advanced Biopharmaceutical Research Institute," within Creative Lab Kobe in the Kobe Biomedical Innovation Cluster, which commenced operations on April 1, 2026. This aims to accelerate biopharmaceutical research and development and the creation of platform technologies.
Last updated: July 19, 2026